A Phase 1 Study in Participants With Advanced Cancer

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

A Phase 1 Study of LY2606368 in Patients With Advanced Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01115790
• Other study ID #: 13129
• Secondary ID: I4D-MC-JTJA
• Status: Completed
• Phase: Phase 1
• First received: April 28, 2010
• Last updated: May 9, 2016
• Start date: February 2010
• Est. completion date: January 2016

Study information

• Verified date: May 2016
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary purpose of Parts A and B of this study is to evaluate the safety and toxicity of prexasertib (an inhibitor of checkpoint kinase 1[chk 1]) in participants with advanced or metastatic cancer (Part A), or squamous cell cancer of the head and neck or squamous cell cancer of any tumor type (Part B). Part C of the study will evaluate prexasertib in three different groups of participants; those with squamous cell cancer of the head and neck that has recurred or spread to other parts of the body, those with squamous non-small cell lung cancer that has recurred or spread, and those with squamous cell cancer of the anus that is not curable by existing therapy.

Description:

Part C added per protocol amendment (February, 2013).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: January 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed

• Have adequate organ function

• Prior Therapies: Systemic treatments: must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy at least 42 days and have discontinued any cytotoxic therapies at least 28 days prior to study enrollment. Radiation therapy and surgery: must be completed at least 4 weeks before study enrollment

• Part A: Must have diagnosis of cancer that is advanced or metastatic

• Part B: Must have histologically confirmed squamous cell cancer of the head and neck or must have squamous cell cancer of any tumor type

• Part C: Must have histological diagnosis of squamous cell cancer of the head and neck, histological or cytological diagnosis of squamous non-small-cell lung cancer, or histological diagnosis of Stage IIIB (N2 or N3) or Stage IV squamous cell cancer of the anus that is not curable by local therapy

• Must be available during the duration of the study and willing to follow the study procedures

• If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug

• If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breast feeding

Exclusion Criteria:

• Must not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatment

• Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C

• Must not have a serious heart condition, such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months

• Must not have systolic blood pressure <90 millimeters of mercury (mmHg) or recurrent symptomatic orthostatic hypotension

• Must not have a family history of long QTc syndrome or be taking drugs known to cause QTc prolongation or Torsades de Pointes

• Must not have a serotonin-secreting carcinoid tumor or a prior history of drug-induced serotonin syndrome

• Must not have acute leukemia

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Advanced Cancer
• Anal Squamous Cell Carcinoma
• Anus Neoplasms
• Carcinoma
• Carcinoma, Non-Small-Cell Lung
• Carcinoma, Squamous Cell
• Carcinoma, Squamous Cell of Head and Neck
• Head and Neck Neoplasms
• Lung Squamous Cell Carcinoma Stage IV
• Neoplasms
• Squamous Cell Carcinoma

Intervention

Drug:
• Prexasertib
Prexasertib IV on day 1 of a 14 day cycle. The expected duration is 3 cycles (2 weeks each for a total of 6 weeks). Participants receiving clinical benefit may remain on study until disease progression, unacceptable toxicity or other criteria for discontinuation are met.

Locations

Country	Name	City	State
United States	University of Texas MD Anderson Cancer Center	Houston	Texas
United States	Sarah Cannon Research Institute SCRI	Nashville	Tennessee
United States	Tennessee Oncology PLLC	Nashville	Tennessee
United States	Peggy and Charles Stephenson Oklahoma Cancer Center	Oklahoma City	Oklahoma
United States	Florida Cancer Specialists	Sarasota	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of a Recommended Phase 2 Dosing Regimen: Maximum Tolerated Dose (Parts A and B)		Time of first dose until last dose (estimated as up to 156 weeks)	Yes
Primary	Determination of Clinically Significant Safety Effects (Parts A and B)		Time of first dose until last dose (estimated as up to 156 weeks)	No
Primary	Percentage of Participants With a Complete or Partial Response (Overall Response Rate) (Part C)		Baseline until disease progression or death from any cause (estimated as up to 24 weeks)	No
Secondary	Percentage of Participants with Complete Response, Partial Response, or Stable Disease (Disease Control Rate) (Parts A, B, and C)		Baseline until disease progression or death from any cause (estimated as up to 24 weeks)	No
Secondary	Progression Free Survival (Parts B and C)		Baseline to measured progressive disease (estimated up to 24 weeks)	No
Secondary	Duration of Response (Parts B and C)		First observation of complete response (CR), partial response (PR), or stable disease (SD) to first observation of progressive disease or death (estimated up to 24 weeks)	No
Secondary	Preliminary Pharmacokinetics of Prexasertib (Cmax) (Parts A, B, and C)		During Cycles 1 and 2	No
Secondary	Preliminary Pharmacokinetics of Prexasertib (AUC) (Parts A, B, and C)		During Cycles 1 and 2	No